In Advance Of HSV-2 Vaccine Trials, Genocea Taps Investors For $35 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
The four-year-old antigen discovery platform developer has added corporate VCs, seeking to broaden its eventual exit opportunities.